Mesothelioma and Asbestos

Prometheus Laboratories Inc. has announced the nationwide commercial launch of ProOnc Mesothelioma Dx as well as two other cancer diagnostic products, ProOnc TumorSource Dx as well as ProOnc Squamous Dx. All three tests are based on highly sensitive, recently developed microRNA technology. MicroRNAs are tiny non-coding sequences of RNA that are vital to many biological as well as pathological processes. By using microRNA-based diagnostic tests, clinicians should be capable to differentiate between various types of cancer tissue to deliver safer as well as more efficacious therapy to their cancer patients.

ProOnc Mesothelioma Dx is a molecular diagnostic test that utilizes microRNA in order to differentiate malignant pleural mesothelioma from both peripheral adenocarcinoma of the lung as well as metastatic carcinomas of the lung as well as pleural tissue.

Prometheus obtained the rights to these diagnostic tests from Rosetta Genomics. Outside the United States, they are marketed as miRview mets, miRview squamous as well as miRview meso.

For the filled story, go to Reuters.